Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23409871 | 1.00 | TGFBR1 (0.61) | TGFBR1MAPK14 | |
| SCHEMBL28822068 | 0.93 | TGFBR1 (0.63) | TGFBR1MAPK14 | |
| SCHEMBL29959769 | 0.92 | TGFBR1 (0.63) | TGFBR1MAPK14 | |
| SCHEMBL28822070 | 0.92 | TGFBR1 (0.63) | TGFBR1MAPK14 | |
| SCHEMBL23409676 | 0.92 | TGFBR1 (0.63) | TGFBR1MAPK14 | |
| SCHEMBL23409675 | 0.90 | TGFBR1 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL29959983 | 0.90 | TGFBR1 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL23409876 | 0.89 | TGFBR1 (0.68) | TGFBR1MAPK14 | |
| SCHEMBL29959691 | 0.89 | TGFBR1 (0.68) | TGFBR1MAPK14 | |
| SCHEMBL23409679 | 0.89 | TGFBR1 (0.58) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4065572-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Origo Biopharma, S.L. (ES) | 2022-10-05 | — | — | EP | claimed |
| CN-114787145-B | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4065572-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Origo Biopharma, S.L. (ES) | 2022-10-05 | — | — | EP | disclosed |